CliffBio
biologic

Rhophylac

Rho(D) Immune Globulin Intravenous (Human)

Loss of exclusivityFebruary 2016projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameRhophylac
Active ingredientRho(D) Immune Globulin Intravenous (Human)
Strength1500IU/ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2004
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rhophylac patent cliff — loss of exclusivity February 2016 | CliffBio